Cartesian Therapeutics
RNAC
64 hedge funds and large institutions have $110M invested in Cartesian Therapeutics in 2024 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 21 increasing their positions, 10 reducing their positions, and 13 closing their positions.
110% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 10
25% more capital invested
Capital invested by funds: $88.3M → $110M (+$22.1M)
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
10.37% more ownership
Funds ownership: 18.38% → 28.75% (+10%)
3% more funds holding
Funds holding: 62 → 64 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$36.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$5.87M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$5.78M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$3.12M |
| 5 |
AC
Armistice Capital
New York
|
+$1.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$8.23M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.97M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$2.43M |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$844K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$811K |
RNAC Hedge Fund Activity: Q3 2024 in Review
64 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q3 2024, worth a combined $110M — up 25% from $88.3M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new RNAC positions and 13 closed out — a net gain of 2 holders — while 21 added to existing stakes and 10 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $36.6M. The largest seller was Artal Group, exiting entirely with an estimated $8.23M sold.
- 64 institutional investors held Cartesian Therapeutics (RNAC) as of Q3 2024, up from 62 in Q2 2024.
- Funds reported $110M of Cartesian Therapeutics stock for Q3 2024, up 25% quarter-over-quarter.
- 15 funds opened new Cartesian Therapeutics positions in Q3 2024 and 13 closed out, a net change of +2 holders.
- The largest Cartesian Therapeutics buyer in Q3 2024 was Fidelity Investments, an estimated $36.6M added.
- The largest Cartesian Therapeutics seller in Q3 2024 was Artal Group, an estimated $8.23M sold.
Based on aggregated 13F filings for Q3 2024.